肝硬変が進行している患者で,正常なインスリン型の成長因子-1濃度を示すアクロメガリー
Ciara Kilcoyne1, Kevin Burke2, Michael W O'Reilly2,3
1Department of Endocrinology, Beaumont Hospital, Dublin 9, Leinster, Ireland ciarakilcoyne@gmail.com.
BMJ case reports
|February 19, 2026
まとめ
このケースは,肝硬変がインスリン類似成長因子-1 (IGF-1) レベルを下げることによって,アクロメガリーをマスクする方法を強調しています. 診断には臨床的評価と成長ホルモン (GH) 検査が必要で,特に肝臓移植がIGF-1を正常化した後は特にそうである.
科学分野:
- エンドクリノロジー エンドクリノロジー
- 肝臓病理学 肝臓病理学
- 腫瘍学 腫瘍学
背景:
- アクロメガリーは,過剰な成長ホルモン (GH) によって引き起こされる珍しい疾患です.
- インスリン類似成長因子-1 (IGF-1) は,GHの作用の重要な媒介者です.
- 肝硬変は,GH/IGF-1軸の調節に影響を与える可能性があります.
研究 の 目的:
- 肝硬変によってマスクされたアクロメガリーのケースを提示するために.
- 診断の課題と必要な臨床判断を強調する.
- GH/IGF-1軸における肝臓の役割を説明します.
主な方法:
- 臨床表現と生化学的評価.
- 成長ホルモン (GH) とIGF-1レベルの評価.
- 経口グルコース耐性検査 (OGTT) による診断確認.
主要な成果:
- 肝硬変によるアクロメガリー症状とGHの上昇が認められたが,肝硬変によるIGF-1は正常であった.
- 診断は,OGTT中の臨床的疑惑とGH非抑制によって確認されました.
- 肝臓移植後のIGF-1レベルが正常化し,アクティブなアクロメガリーが確認されました.
結論:
- 肝硬変は,偽りの正常なIGF-1レベルにつながり,アクロメガリーをマスクします.
- 臨床的評価とGH検査は,特定の文脈でのアクロメガリーの診断に不可欠です.
- 肝臓はGH/IGF-1のバランスを維持する上で重要な役割を果たします.
関連する概念動画
Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Type I Diabetes III: Clinical Manifestations
26
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the...
26
Type II Diabetes II: Pathophysiology
28
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
28
Hyperglycemia
25
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
25
Cirrhosis I: Introduction
28
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
28
Cirrhosis II: Pathophysiology
42
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
42


